NasdaqGM - Nasdaq Real Time Price USD

Fulcrum Therapeutics, Inc. (FULC)

5.68

+0.31

+(5.77%)

At close: May 12 at 4:00:01 PM EDT

5.80

+0.12

+(2.11%)

After hours: May 12 at 7:08:20 PM EDT

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or th

GlobeNewswire 3 days ago

FULC
+5.77%
Fulcrum Therapeutics to Participate in Upcoming May Conferences

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences: H.C. Wainwright BioConnect Investor Conference at NASDAQMay 20, 2025New York, New York RBC Capital Markets Global Healthcare ConferenceMay 21, 2025Fireside

GlobeNewswire 4 days ago

FULC
+5.77%
Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ...

Fulcrum Therapeutics Inc (FULC) reports reduced expenses and advances in clinical trials, positioning itself for future growth despite competitive challenges.

GuruFocus.com 10 days ago

FULC
+5.77%
Q1 2025 Fulcrum Therapeutics Inc Earnings Call

Q1 2025 Fulcrum Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 10 days ago

FULC
+5.77%
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended Q1 2025 with $226.6 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 01

GlobeNewswire 11 days ago

FULC
+5.77%
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the result

GlobeNewswire 18 days ago

FULC
+5.77%
We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. last month

FULC
+5.77%
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on March 11, 2025 at 8:40 am ET. The webcast of the fireside chat will be accessible HERE and by vi

GlobeNewswire 2 months ago

FULC
+5.77%
Fulcrum Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Fulcrum Therapeutics ( NASDAQ:FULC ) Full Year 2024 Results Key Financial Results Revenue: US$80.0m (up by US$77.2m...

Simply Wall St. 2 months ago

FULC
+5.77%
Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

Despite a quarterly revenue dip, Fulcrum Therapeutics Inc (FULC) strengthens its cash position and advances key programs, setting a robust foundation for future growth.

GuruFocus.com 2 months ago

FULC
+5.77%
Q4 2024 Fulcrum Therapeutics Inc Earnings Call

Q4 2024 Fulcrum Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

FULC
+5.77%
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended 2024 with $241.0 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical

GlobeNewswire 2 months ago

FULC
+5.77%
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 25, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to

GlobeNewswire 2 months ago

FULC
+5.77%
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 at 1:20 pm ET. The webcast of the fireside chat will be accessible HER

GlobeNewswire 3 months ago

FULC
+5.77%
Fulcrum Therapeutics Insider Ups Holding During Year

Viewing insider transactions for Fulcrum Therapeutics, Inc.'s ( NASDAQ:FULC ) over the last year, we see that insiders...

Simply Wall St. 3 months ago

FULC
+5.77%
Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago

Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders will doubtless be very grateful to see the share price up 40...

Simply Wall St. 4 months ago

FULC
+5.77%
Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why

Fulcrum Therapeutics (FULC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 5 months ago

FULC
+5.77%
Fulcrum Therapeutics to Participate in Upcoming December Conferences

CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences: Piper Sandler 36th Annual Healthcare ConferenceDecember 3, 2024Fireside Chat at 12:00 pm ET, Participation link: HERENew York, New York Citi 2024 Global He

GlobeNewswire 5 months ago

FULC
+5.77%
Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)

Fulcrum Therapeutics ( NASDAQ:FULC ) Third Quarter 2024 Results Key Financial Results Net loss: US$21.7m (loss narrowed...

Simply Wall St. 5 months ago

FULC
+5.77%
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...

Despite a strong cash position and promising pipeline developments, Fulcrum Therapeutics Inc (FULC) faces hurdles with reduced revenues and ongoing net losses.

GuruFocus.com 5 months ago

FULC
+5.77%

Performance Overview

Return	FULC	S&P 500 (^GSPC)
YTD	+20.85%	-0.64%
1-Year	-23.96%	+11.90%
3-Year	-24.97%	+48.70%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics to Participate in Upcoming May Conferences

Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ...

Q1 2025 Fulcrum Therapeutics Inc Earnings Call

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Fulcrum Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

Q4 2024 Fulcrum Therapeutics Inc Earnings Call

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Fulcrum Therapeutics Insider Ups Holding During Year

Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)

Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...

Performance Overview